Odyssey Therapeutics is a stock with meaningful, current analyst coverage. Reviewing the most recent individually attributed targets from each covering firm yields six distinct price objectives: $27 (UBS, initiated Buy in October 2026), $29 (J.P. Morgan, Overweight, raised from $26 in August 2026), $30 (Wedbush, Outperform), $40 (Oppenheimer, Outperform), $40 (H.C. Wainwright, Buy), and $42 (Raymond James, initiated Outperform in October 2026).
The arithmetic mean of these six targets is about $34.67, which rounds to the $35 central target used here. The range is wide — roughly $27 to $42 — reflecting genuine disagreement about how much the pipeline is worth. All six firms rate the shares positively, but there is no "hold" or "sell" view among those publishing targets, which is itself a notable skew.
Analyst reasoning centers overwhelmingly on ODTX's lead candidate OD-001, an oral RIPK2 scaffolding inhibitor that has shown proof-of-concept results in ulcerative colitis, with the ulcerative colitis market often cited as a roughly $10 billion opportunity. H.C. Wainwright previously carried a $44 target before most recently setting $40, while J.P. Morgan's earlier $26 target was lifted to $29 — a sign of modestly shifting assumptions rather than a unanimous, stable consensus. These are individual research opinions, not a guarantee of future performance.
At its latest verified close near $19.23, Odyssey Therapeutics would need to rise roughly 82% to reach $35 — a very large move by any standard. The company listed on Nasdaq in May 2026 at an $18 IPO price, raising roughly $279 million in an upsized offering alongside a concurrent private placement, and its 52-week range spans $15.10 to $29.05.
The path to $35 is fundamentally a clinical-development story. As a pre-revenue company, ODTX reported a net loss of roughly $177.6 million over the trailing twelve months and negative EPS (earnings per share), meaning the investment case rests on advancing OD-001 and a broader pipeline — including OD-002 (an SLC15A4 inhibitor) and OD-003 (a TNFR2 agonist) — rather than near-term profitability. Reaching the target would require the stock to trade decisively above its prior $29.05 high and sustain a premium valuation built on trial execution.
The shares' 52-week range of $15.10 to $29.05 frames the technical picture. The $29 area represents a meaningful prior resistance level, while the $18 IPO price sits near current levels and the $15 zone marks the 52-week low and a key support level. Because the $35 target sits roughly 20% above the 52-week high, reaching it would require a breakout to new highs rather than a move within the existing trading range.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms do not all publish identical time frames. Investors should monitor trial initiation and data-readout timing for OD-001, upcoming quarterly earnings and cash-burn updates, analyst target revisions, and any regulatory or financing developments. No definitive forecast should be assumed from the target itself.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For those tracking names like ODTX, pairing fundamental research with AI-generated signals can add a useful, data-driven layer to the decision-making process.
The $35 target is an analyst-derived average — roughly $34.67 across six current, verified price objectives — and it requires a very large move of about 82% from the latest price near $19.23. The case for the move rests on OD-001's clinical promise, a well-capitalized balance sheet, and uniformly bullish sell-side coverage, while the principal obstacles are binary trial risk, continued losses and potential dilution, and the need to break convincingly above the $29 prior high. The wide $27-to-$42 analyst range underscores genuine uncertainty, and no outcome is guaranteed. Investors should watch trial progress and cash position above all else.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.